|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The MCPH1 p.Arg304ValfsTer3 carrier breast tumors showed recurrent tumor suppressor gene TP53 mutations, which were also significantly over-represented in breast tumors with somatically inactivated MCPH1.
|
30809794 |
2019 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We identified 5 genes (WNK2, RUNX1T1, CTNNB1, TSC1, and TP53) harboring somatic mutations that correlated with early tumor recurrence after curative resection in 182 primary HCC samples.
|
31349001 |
2019 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Thirty-two (44.4%) had at least one p53-positive margin, and there was a significant association between the expression of p53 and tumor recurrence (<i>P</i><0.001). p53-positive expression was correlated with RFS in patients with dysplastic margins, and its expression in moderate/severe dysplastic groups had a worse RFS than mild dysplastic groups.
|
30863157 |
2019 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The p53 and Ki-67 expression didn't associate significantly with tumor recurrence.p63 and cyclinD1 exhibited significant hazard ratios.
|
28488128 |
2018 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Preoperative clinical symptoms, upper thoracic location, ulcerative or intraluminal mass macroscopic tumor type, tumor invasion depth level, basaloid histology, angiolymphatic invasion, tumor thickness, submucosal invasion thickness, diameter of the largest single tongue of invasion, and complete negative aberrant p53 expression were significantly related to tumor recurrence and/or recurrence-free survival.
|
30568392 |
2018 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
It should be considered that a strong immunopositivity of p53 and higher Ki-67 LI could predict an increased risk of tumor recurrence, but more studies and larger series are expected to confirm and enlarge the diagnostic and therapeutic management process of these lesions.
|
27215912 |
2017 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of TP53 mutation-associated miR-182 may promote tumor cell proliferation and migration in HNSCC and suggest possible biomarker for the prediction of tumor recurrence.
|
27744260 |
2017 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The present results indicate that it is possible to detect mutated p53 genes with the cirDNA and that this could be used as a biomarker of tumor recurrence during the clinical evolution of the transplanted patients.
|
27753013 |
2016 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Targeted next-generation sequencing (NGS) revealed the presence of both a TP53 mutation and a PTEN deletion in the cartilaginous and the noncartilaginous components of the recurrent tumor.
|
27248819 |
2016 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Racial differences in TP53 mutation, PAM50 basal subtype, and triple-negative tumor prevalence but not intratumor genetic heterogeneity influenced the magnitude and significance of the racial disparity in tumor recurrence.
|
26371147 |
2015 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Given that GPX-1 is shown to be a target of p53, these results suggest that p53 mutations play a role in tumor recurrence and malignant transformation of GCTB through interactions with GPX-1.
|
23748877 |
2013 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The aim here was to investigate stage T1 tumors regarding MDM2 promoter SNP309 polymorphism, mutations in the p53 gene, and expression of p53 and p16 measured by immunohistochemistry, and subsequently relate these changes to tumor recurrence and progression.
|
23356517 |
2013 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recent evidence suggests that oxidative stress in stroma may play a role in cancer progression, and loss of p53 function in the stromal cells was associated with poor prognosis and high tumor recurrence.
|
23376231 |
2013 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
|
21061181 |
2011 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemical and genetic analysis revealed p53 overexpression in the tumor giant cells and loss of heterozygosity of p53 gene only in the recurrent tumor; thus, a diagnosis of secondary malignant giant-cell tumor was finally made.
|
21924561 |
2011 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53.
|
21487231 |
2010 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The MIB-1 index and the percent of p53 protein-positive cells in the primary tumor were 4.6% and 35.4%, respectively, whereas those of the recurrent tumor were 34.7% and 33.1%, respectively.
|
19533187 |
2009 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
A positive p53 immunostaining was strongly associated with presence of exon 5-8 mutations (P<0.0001), advanced pT-stage (P<0.0001), high Gleason grade (P<0.0001), positive surgical margins (P=0.03) and early biochemical tumor recurrence (P<0.0001).
|
18552821 |
2008 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In the subgroup of 92 patients with superficial pTa-T1 bladder tumors we did not find that the TP53 or FGFR3 genotype alone or combined had a predictive value for tumor recurrence.
|
17085196 |
2006 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Both PTEN and p53 staining may be good indicators of clinical stage and probability of tumor recurrence in EC.
|
15583796 |
2005 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
By a combination analysis, HCCs with PAP expression alone showed the lowest frequency of p53 mutation (P < 0.036), the highest rates of grade 1 and low-stage tumors (P < 0.007 and P < 0.001, respectively), less frequent early tumor recurrence (P = 0.051), and hence a better 5-year survival (P = 0.044) than groups expressing PAP and REG1A, REG1A alone, and neither PAP or REG1A.
|
15814635 |
2005 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
By univariate analysis, TOP2alpha index (p=0.0267), HER2 score (p =0.028) and p53 index (p=0.0188) were significantly and loss of TOP2alpha gene (p=0.0575) tendentially correlated with tumor recurrence, while loss of HER2 gene (p=0.069) and loss of p53 gene (p=0.0587) were tendentially correlated with tumor progression.
|
15816547 |
2005 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Younger age (< or = 55 years; p=0.00001), hepatitis B surface antigen (HBsAg) in serum (p=0.00001), p53 mutation (p=0.008), large tumor (p=0.00001), vascular invasion (p=0.00001) and early tumor recurrence (p=0.00001) were significant associates of high AFP, while anti-HCV in serum and beta-catenin mutation in HCC had less frequent high AFP (p=0.013 and < 0.0001, respectively).
|
15305374 |
2004 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The OPN overexpression was associated closely with alpha-fetoprotein elevation (P = 0.001), p53 mutation (P = 0.021), larger tumors (P = 0.002), high-grade HCC (P < 0.001), late-stage HCC (P < 0.001), early tumor recurrence and/or metastasis (P = 0.003), and a lower 10-year survival rate (P = 0.00013).
|
12833464 |
2003 |
|
Recurrent tumor
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In cases in which the tumor was partially removed, mutation of p53 protein and expression of hTERT mRNA predicted increased doubling time for residual tumor as well as the probability of tumor recurrence.
|
12691407 |
2003 |